Determine the extent to which we can screen for and reconstruct visual field defects based on an analysis of eye movement behaviour.
ID
Source
Brief title
Condition
- Vision disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Eye movement characteristics and changes therein over time in patients and
control participants.
Secondary outcome
Viewing priority maps, calculated based on eye-movement data according to
Marsman et al. (2016). Correlations between viewing priority maps and VF maps
obtained using SAP. Latency and accuracy measures based on ETT, correlations
between these measures and VF maps (mean deviations) obtained using SAP.
Classification accuracy of the machine learning classifier.
Background summary
There are several (neurodegenerative) conditions, which lead to visual field
defects (VFD). One example is Hemianopia, where one half of the visual field
(left or right of the vertical midline) is missing due to damage in the
contralateral visual cortex. Another common cause for visual field deficits is
glaucoma, which is characterized by damage at the optic nerve head. The
currently most widely used method to assess visual field defects is automated
perimetry. This method, however, can be hard to use in various patient groups,
as it requires the patient to focus on a hard task for a long time. Using
eye-movements may help simplify this type of assessment.
We will investigate the usage of eye movement recordings to assess visual field
defects.
More precisely, we will test and improve two alternative methods for screening
for VFD based on measuring eye-movements. The tests will be simpler, shorter,
more enjoyable, and less fatiguing than currently used ones. Therefore, we
expect these to facilitate the screening for visual field defects.
We are also going to investigate the retest reliability of our two tests. We
will invite our participants a second time after several weeks to do the tests
again.
Study objective
Determine the extent to which we can screen for and reconstruct visual field
defects based on an analysis of eye movement behaviour.
Study design
Explorative, observational case-control study.
Study burden and risks
All involved tests are non-invasive, and cause no increase in risk.
Participation requires (additional) time to complete screening, questionnaires
and the behavioural tasks. Only the healthy participants will undergo a routine
ophthalmic screening test to rule out ophthalmic problems such as the presence
of a visual field defect. For patients, their ophthalmic eye status is already
known. In study 1 and 2 patients and healthy participants will perform a
cognitive screening test (the Montreal Cognitive Assessment (MoCA)). If any
abnormal screening results are obtained, they will be referred to their GP.
Detection of signs of an eye condition or cognitive impairment may come as an
unexpected, unpleasant surprise. However, an early diagnosis will allow
treatment to be initiated and therefore result in more preservation of visual
or cognitive functioning. Taking part in the study will not interfere with
ongoing treatment of the patients.
Ant. Deusinglaan 2
Groningen 9713 AW
NL
Ant. Deusinglaan 2
Groningen 9713 AW
NL
Listed location countries
Age
Inclusion criteria
Patients: the presence of a visual field defect;
Exclusion criteria
Patients: cognitive impairment (blind MoCA score below 18 out of 22)
Healthy participants: any evidence for an eye disease/visual field loss coming from the screening or questionnaire: intraocular pressure above 21 mmHg, positive family history of glaucoma, questionnaire results that indicate the presence of any ophthalmic abnormality (exceptions are made for prescription glasses or a previous cataract extraction), cognitive impairment (blind version MoCA score below 18 out of 22)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL65230.042.18 |
| Other | UMCG Register and NTR |